BioSpace News Archive

Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter “Hisamitsu Pharmaceutical”), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc., announces that a New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia

Brightree to innovate and expand adoption of Apacheta’s mobile delivery solution to more HME customers

SonarMD partners with payer organizations and specialist groups to improve care for “high beta” patients

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Rectal Suppository, 1000 mg, the first generic version of Allergan’s Canasa® Rectal Suppository, 1000 mg.

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Mesalamine Delayed-Release Tablets USP, 1.2 g, a generic version of Shire’s Lialda® Delayed-Release Tablets.

Using analytics and data wrapped around a tele-remote service model, EHN will offer a best in-class program to high need populations around Texas.

Physicians’ Education Resource® (PER®), the nation’s leading resource for oncology and hematology continuing medical education (CME), announces the full agenda for the 36th Annual Miami Breast Cancer Conference®

Tivic Health, a bioelectronic device company, will demonstrate ClearUP™ Sinus Pain Relief – the first bioelectronic treatment for sinus pain at CES 2019.

McCann Health agencies were recognized with top honors across the Asia-Pacific region at the Campaign Magazine Asia-Pacific “Agency of The Year Awards” 2018.

Transgene (Paris:TNG) today announced its financial reporting dates for 2019